BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

  • BiondVax Pharmaceuticals Ltd BVXV announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. 
  • The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial.
  • But the untreated control group's weight declined 12% on average, a highly statistically significant difference.
  • The prophylactic results follow previously reported data from the same study indicating that compared to the control (placebo) group, hamsters treated with a 2mg dose of BiondVax's inhaled NanoAb one day after infection had negligible SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness in comparison to the placebo group that had at least 30-times higher viral titers
  • This preclinical trial continues with additional arms testing lower therapeutic doses (0.66mg and 0.22mg). In 2023, BiondVax is expected to conduct a preclinical toxicity study. 
  • The company also expects to scale up its manufacturing processes for NanoAbs for the first-in-human Phase 1/2a trial, which is planned for Q4 2023.
  • Price Action: BVXV shares are up 2.55% at $2.82 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!